BioMarin Pharmaceutical has struck a deal to purchase fellow biotechnology firm Amicus Therapeutics for about $4.8 billion in money.
Source link
BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion
Related Posts
The Best After-Christmas Deals on Gear We’ve Tested (2025)
After-Christmas offers are a superb option to redeem any reward playing cards or money you bought for Christmas. You should…
U.S. stocks retreat from highs as Broadcom leads tech sell-off
Signage on the Broadcom Inc. headquarters in San Jose, California, U.S., on Monday, June 2, 2025. David Paul Morris |…
Blue Origin launchpad may not be restored until 2028: NASA’s Isaacman
NASA Administrator Jared Isaacman on Monday instructed CNBC that it’s going to “take some severe time” to revive the launchpad…